ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $79.75.
Several equities analysts have recently issued reports on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday.
Get Our Latest Stock Analysis on ANIP
Insider Activity
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $166,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. 76.05% of the stock is owned by institutional investors.
ANI Pharmaceuticals Price Performance
ANIP stock opened at $62.49 on Wednesday. The company has a fifty day moving average price of $58.40 and a 200-day moving average price of $58.06. The company has a market capitalization of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.62. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- How to Build the Ultimate Everything ETF Portfolio
- Airline Stocks – Top Airline Stocks to Buy Now
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Does a Stock Split Mean?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.